Vimarsana
Biggest News Aggregation in the World

Page 28 - Alacyclovir News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alacyclovir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alacyclovir Today - Breaking & Trending Today

Gilead Says Counterfeiting Network Sold $250 Mln Worth of Its HIV Drugs - Vimarsana News

Gilead Says Counterfeiting Network Sold $250 Mln Worth of Its HIV Drugs

Gilead Sciences said on Tuesday that tampered and counterfeit versions of its HIV treatments worth $250 million were sold to pharmacies over 2 years by a network of drug distributors and suppliers.

PharmaMar Shares Soar After Drug Study Suggests Efficacy Against Omicron - Vimarsana News

PharmaMar Shares Soar After Drug Study Suggests Efficacy Against Omicron

Shares in PharmaMar jumped almost 20% on Tuesday after the Spanish drugmaker said lab trials suggested its Plitidepsin drug was effective against the main COVID-19 variants, including the highly contagious Omicron.

Pfizer to Supply US With 10 Mln More Courses of COVID-19 Pills - Vimarsana News

Pfizer to Supply US With 10 Mln More Courses of COVID-19 Pills

The Biden administration has doubled its order for Pfizer's oral COVID-19 antiviral treatment, the company and the White House said on Tuesday.

MHRA Approves Third COVID Antiviral Pill - Vimarsana News

MHRA Approves Third COVID Antiviral Pill

Pfizer's antiviral drug Paxlovid, which contains a combination of PF-07321332 and ritonavir, has been approved by the MHRA for use in those with mild to moderate COVID-19 at risk of developing more severe disease.

Japan Health Panel Approves Merck's Oral COVID-19 Treatment - Vimarsana News

Japan Health Panel Approves Merck's Oral COVID-19 Treatment

A Japanese health ministry panel recommended approval of the COVID-19 antiviral pill developed by Merck last week, part of plans by Prime Minister Fumio Kishida to roll out new treatments by year's end.